Omalizumab versus cyclosporin-A for the treatment of chronic spontaneous urticaria: can we define better-responding endotypes?

• Egile Nagusiak: Emek Kocatürk (Egilea), Emel Bülbül Başkan (Egilea), Özlem Su Küçük (Egilea), Mustafa Özdemir (Egilea), Sinem Örnek (Egilea), Pelin Kuteyla Can (Egilea), Eda Hașal (Egilea), Burhan Engin (Egilea), Nilgün Atakan (Egilea), Erkan Alpsoy (Egilea)
• Formatua: Liburua
• Argitaratua: Sociedade Brasileira de Dermatologia, 2022-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Abstract Background: Chronic Spontaneous Urticaria (CSU) is characterized by recurrent wheals and/or angioedema for longer than 6-weeks. Guidelines recommend Omalizumab (Oma) as first-line and Cyclosporine-A (Cs-A) as second-line treatment in antihistamine resistant CSU. This step-wise algorithm mig...